BioCardia commercially launches Morph DNA steerable introducer product family

BioCardia, Inc.

Morph DNA steerable introducer family now commercially available; currently used in ongoing cell-therapy clinical trials.
CEO Peter Altman says sales pipeline explored organically without a direct sales force or third-party partners.
Anticipates final results of CardiAMP Heart Failure I trial and active enrollment in CardiAMP Heart Failure II by Q1 2025.
Company remains focused on its FDA breakthrough-designated cell therapy for ischemic heart failure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.